证券代码：688656 证券简称：浩欧博 公告编号：2025-021 表决情况：5 票同意，0 票反对，0 票弃权，关联董事刘青新先生、熊峰先生回 避表决，同意的票数占全体非关联董事所持的有表决权票数的 100%。 2. 审议通过《关于调整公司 2023 年限制性股票激励计划首次授予价格的议 案》 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）披露的《江苏浩 欧博生物医药股份有限公司关于调整 2023 年限制性股票激励计划首次授予价格的 公告》。 江苏浩欧博生物医药股份有限公司 第三届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏浩欧博生物医药股份有限公司（以下简称"公司"）第三届董事会第十九 次会议于 2025 年 4 月 4 日发出通知，并于 2025 年 4 月 9 日 10 时以通讯方式召开。 本次会议应出席董事 7 名，实际出席董事 7 名，会议由公司董事长 JOHN LI 先生主 持。公司监事及高级管理人员列席了会议。本次会议的召集 ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-020 江苏浩欧博生物医药股份有限公司 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，副董事长王凯先生主持，会议以现场投票及网络投票相结合的方式进 行表决。本次会议的召集、召开与表决程序符合《公司法》及《公司章程》的规定，会议合法有效。 （五）公司董事、监事和董事会秘书的出席情况 1、公司在任董事7人，出席7人； 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 二、议案审议情况 （一）非累积投票议案 1、议案名称：关于《公司2024年年度报告》及其摘要的议案 审议结果：通过 表决情况： ■ 2、议案名称：关于《公司董事会2024年度工作报告》的议案 审议结果：通过 2、公司在任监事3人，出席3人； 3、董事会秘 ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-020 江苏浩欧博生物医药股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 114 | | --- | --- | | 普通股股东人数 | 114 | | 2、出席会议的股东所持有的表决权数量 | 47,395,341 | | 普通股股东所持有表决权数量 | 47,395,341 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 76.1285 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 76.1285 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，副董事长王凯先生主持，会议以现场投票 （一） ...

国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于江苏浩欧博生物医药股份有限公司 2024 年年度股东大会的法律意见书 致：江苏浩欧博生物医药股份有限公司 江苏浩欧博生物医药股份有限公司（以下简称"公司"）2024 年年度股东大会 定于 2025 年 4 月 7 日召开，国浩律师（上海）事务所（以下简称"本所"）接受 公司的委托，指派陈晓纯律师、李嘉言律师（以下简称"本所律师"）对本次股东 大会进行见证，并依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会发布 的《上市公司股东会规则》及其他现行有效的法律、法规及规范性文件规定及《江 苏浩欧博生物医药股份有限公司章程》（以下简称"《公司章程》"）出具本法律意 见书。 本所律师按照中华人民共和国（以下简称"中国"，仅为本法律意见书之目的， 不包括香港特别行政区、澳门特别行政区和台湾地区）现行法律、法规的规定， 列席了本次股东大会，审查了公司提供的有关本次股东大会各项议程及相关文件， 对本次股东大会的召集、召开程序是否合法及是否符合《公司章程》规定、出席 会议人员资格和 ...

截至2025年3月28日收盘，浩欧博（688656）报收于89.0元，较上周的88.98元上涨0.02%。本周，浩欧 博3月28日盘中最高价报93.0元。3月24日盘中最低价报82.41元。浩欧博当前最新总市值60.73亿元，在 医疗器械板块市值排名48/124，在两市A股市值排名2423/5140。 本周关注点 公司公告汇总 华泰联合证券有限责任公司发布关于江苏浩欧博生物医药股份有限公司2024年度持续督导跟踪报告。报 告指出，公司面临的风险包括新产品研发和注册风险、核心技术泄密及核心技术人员流失风险、新业务 拓展不及预期风险、酶联免疫法产品被化学发光产品替代风险、食物特异性IgG检测产品相关风险、财 务风险、行业风险和宏观环境风险。报告期内，公司实现营业收入40,233.91万元，同比增长2.01%；归 属于上市公司股东的净利润3,680.38万元，同比下降22.24%。主要财务指标变动原因包括宏观经济环境 波动、脱敏药"欧脱克"的临床相关费用投入、股权激励股份支付费用增加、募投项目投入使用导致折旧 摊销费用增加及闲置募集资金购入银行理财产品收益减少。公司核心竞争力未发生重大不利变化，将继 续巩固过敏检测 ...

Core Viewpoint - The report outlines the continuous supervision and tracking of Jiangsu Haooubo Biopharmaceutical Co., Ltd. by Huatai United Securities, highlighting the company's financial performance, risks, and core competitiveness in the in vitro diagnostic reagent industry. Group 1: Risk Factors - The company faces risks related to new product development and registration, as the in vitro diagnostic reagent industry requires significant time and investment for product approval [1][2]. - There is a risk of core technology leakage and loss of key personnel, which could lead to economic losses for the company [2]. - The company may encounter challenges in expanding new business lines, particularly with the Oduoke series products, which are currently limited to specific regions and require effective marketing efforts [2][3]. - The enzyme-linked immunosorbent assay (ELISA) products may be at risk of being replaced by chemiluminescence products due to the latter's technological advantages [3]. - The food-specific IgG testing products face scrutiny regarding their clinical significance, which could impact sales if regulatory bodies withdraw approval [4]. Group 2: Financial Performance - For the year 2024, the company's operating income was approximately 402.34 million yuan, reflecting a 2.01% increase compared to 2023 [9]. - The net profit attributable to shareholders decreased by 22.24% to approximately 36.80 million yuan, primarily due to increased clinical expenses for the Oduoke product and higher stock incentive costs [10]. - The company's total assets increased by 8.80% to approximately 1.03 billion yuan, while the net assets attributable to shareholders rose by 0.17% [9]. Group 3: Core Competitiveness - The company aims to solidify its market share in the allergy testing field and expand its presence in the autoimmune testing sector through advanced chemiluminescence technology [11]. - With over 300 million allergy patients in China, the allergy testing market presents significant growth potential, and the company has established a comprehensive product menu and scale advantages [11][12]. - The company has developed a nationwide sales and service network, with approximately 700 distributors, enhancing its market reach and brand influence [12]. - Continuous investment in research and development is evident, with R&D expenses amounting to approximately 46.27 million yuan, representing 11.50% of operating income [13].

Group 1 - The core viewpoint of the report is to summarize the sponsorship and regulatory compliance of Jiangsu Haobio Pharmaceutical Co., Ltd. during its initial public offering (IPO) on the Sci-Tech Innovation Board [1] - The issuer, Jiangsu Haobio Pharmaceutical Co., Ltd., has a registered capital of 63.058328 million yuan and was listed on January 13, 2021 [1] - The sponsor, Huatai United Securities Co., Ltd., conducted due diligence and prepared application documents in accordance with relevant laws and regulations [1][3] Group 2 - During the continuous supervision period, the sponsor conducted on-site inspections to check the use of raised funds, project progress, and corporate governance [3][4] - The sponsor identified non-operating fund occupation by related parties and conducted a special on-site inspection, requiring the company to strengthen internal training and governance [3][10] - The sponsor issued 26 verification opinions on the issuer's use of raised funds and related transactions, with no disapproval opinions issued [6][13] Group 3 - The issuer established a special account for raised funds and signed a tripartite supervision agreement with the sponsor and relevant banks [4] - The issuer's actual controller was involved in non-operating fund occupation, leading to internal penalties and a requirement to return the occupied funds [8][11] - The issuer's compliance with information disclosure requirements was affirmed, with no undisclosed matters identified [12][13] Group 4 - The report indicates that the issuer strictly followed regulations regarding the use of raised funds and fulfilled information disclosure obligations accurately [13] - The sponsor will continue to oversee the use of funds for the "New In Vitro Diagnostic Reagent R&D Center Project" until all funds are utilized [13]

保荐总结报告书 华泰联合证券有限责任公司 关于江苏浩欧博生物医药股份有限公司 首次公开发行股票并在科创板上市 之保荐总结报告书 | 保荐机构名称 | 华泰联合证券有限责任公司 | | --- | --- | | 保荐机构编号 | Z26774000 | 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监 会"）、上海证券交易所对保荐总结报告书相关事项进行的任何质询和调查。 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 二、保荐机构基本情况 | 情况 | 内容 | | --- | --- | | 保荐机构名称 | 华泰联合证券有限责任公司 | | 注册地址 | 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金 | | | 小镇 B7 栋 401 | | 主要办公地址 | 上海市浦东新区东方路 18 号保利广场 E 座 20 楼 | | 法定代表人 | 江 ...

华泰联合证券有限责任公司 关于江苏浩欧博生物医药股份有限公司 2024 年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：江苏浩欧博 | | --- | --- | | 保荐代表人姓名：孙圣虎 | 联系电话：021-38966920 | | 保荐代表人姓名：董雪松 | 联系电话：021-38966912 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为江苏浩欧博生物医药股份有限公 司（以下简称"浩欧博"、"公司"或"发行人"）首次公开发行股票的保荐机 构，对浩欧博进行持续督导，并出具本持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 无。 二、重大风险事项 公司面临的风险因素主要包括： 1、核心竞争力风险 （1）新产品研发和注册风险 体外诊断试剂行业是国内新兴的生物制品行业，随着医疗卫生事业的快速发 展，我国对体外诊断试剂产品的要求不断提高，市场需求也在不断变化。作为技 术密集型行业，不断研发出满足市场需求的新产品是公司在 ...

Core Viewpoint - The article discusses the significant increase in pollen levels in Beijing due to a warm winter, leading to a surge in allergy cases and a corresponding rise in the demand for allergy medications, indicating a booming market for allergy-related pharmaceuticals [1][8][9]. Industry Overview - The allergy medication market in China is projected to experience rapid growth, potentially exceeding $20 billion by 2030, driven by an increasing patient population and rising awareness of allergy conditions [8][9]. - Currently, there are approximately 500 million patients in China suffering from allergic diseases such as allergic rhinitis, asthma, atopic dermatitis, and chronic obstructive pulmonary disease [8]. Market Dynamics - Recent data shows a 40% year-on-year increase in the purchase of allergy-related medications, with a 127% day-on-day increase in orders since March 20 in Beijing [8]. - Popular allergy medications like Loratadine and its upgraded version Desloratadine have seen significant sales growth, with Loratadine's retail market sales surpassing 7.6 billion yuan in the past five years, maintaining an annual growth rate of over 10% [10][11]. Competitive Landscape - The allergy medication market is characterized by numerous players, primarily traditional pharmaceutical companies that have historically relied on generic drugs [10]. - New entrants are focusing on innovative drug development, including small molecule targeted drugs and biological agents, with over 1,600 clinical trials related to allergies registered globally [12][13]. Emerging Trends - A new biological drug, Dupilumab, has been approved for treating seasonal allergic rhinitis, showing promising results in clinical trials [13]. - The high pricing of biological drugs presents a challenge for patient acceptance, as many patients prefer cost-effective options despite the superior efficacy of these new treatments [15]. Treatment Innovations - Desensitization therapy is gaining attention as a long-term solution for allergies, although it requires a lengthy treatment period [16][17]. - Companies like Iwubio are already seeing sales growth in desensitization products, indicating a potential shift in treatment preferences among patients [17]. Future Outlook - The allergy medication market in China is still in its early stages, with many companies vying for a share of this lucrative sector, awaiting the emergence of the next blockbuster product [19].